key: cord-0266750-6f6bkf2y authors: Madera, J. D.; Ruffino, A. E.; Feliz, A.; McCall, K. L.; Piper, B. J. title: Declines and pronounced regional disparities in prescription opioid use in the United States date: 2021-12-05 journal: nan DOI: 10.1101/2021.12.02.21266660 sha: 180f36f82217686c38a9d0d1f0502333d8a66cb8 doc_id: 266750 cord_uid: 6f6bkf2y Background. The United States (US) opioid epidemic is a persistent and pervasive public health emergency as it continues to claim the lives of Americans through addiction and overdose. There have been sustained efforts to reverse this iatrogenic crisis over the past decade. This study analyzed the changes in prescription opioid distribution for pain and identified regional differences between 2010 and 2019. Methods and Findings. Opioid production data was obtained from the DEAs annual production quotas. Total opioid production has decreased 41.5% from 2013 (87.6 morphine mg equivalent metric tons) to 2019 (51.3). Opioid distribution from 2010 to 2019 was collected for ten prescription opioids (codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol) from the US Drug Enforcement Administrations Automation of Reports and Consolidated Orders System. Regional variance was expressed as the ratio of the 95th to 5th percentiles of opioid distribution per state, corrected for population. The peak year for all ten prescription opioids was identified, individually, as between 2010 and 2013, except for codeine (2015). There was a 51.96% overall decrease in opioid distribution per capita with the largest decrease in Florida (-61.61%) and smallest in Texas (-18.64%). The largest quantities of opioid distribution were observed in Tennessee (520.70 morphine mg equivalent or MME per person) and Delaware (251.45) in 2011 and 2019. The smallest was Nebraska (153.39) in 2011 and Minnesota (90.49) in 2019. The highest to lowest state ratio of total opioid use, corrected for population, was sizable in 2011 (5.25) and 2019 (2.78). Similarly, the mean 95th/5th ratio was relatively stable in from 2011 (4.78 +0.70) and 2019 (5.64+0.98). The 95th/5th ratio in 2019 was greatest for methadone (10.23) and oxymorphone (10.09) and smallest for morphine (2.20) and fentanyl (2.12). Southern states (e.g MS, TN, AL, AK, DE, and NC) had the highest per capita distribution for eight of the ten opioids in 2019. The strength of the correlation between per capita hydrocodone and codeine, and hydromorphone and codeine increased significantly from 2011 to 2019. Conclusions. This study found a decline in total production and distribution for ten prescription opioids during the last half-decade. However, distribution was non-homogeneous at a state level. Analysis of regional differences revealed a three-fold difference in the 95th:5th percentile ratio between states which was unchanged over the past decade. Future research focused on identifying factors contributing to the observed regional variability could prove valuable to understanding, and potentially remediating, the pronounced disparities in prescription opioid use in the US. Joshua D. Madera, Amanda E. Ruffino, Adriana Feliz, Kenneth L. McCall, Brian J. Piper Drug overdoses are largely driven by opioids in the United States (US) and not only continue to escalate but also exceeded one-hundred thousand in one-year [1] . Despite knowledge of the risks of addiction and overdose, illicit and prescription opioids continue to have a strong presence throughout the US. The opioid prescription per capita increased by 7.3% between 2007 and 2012 with larger elevations in pain medicine (8.5%) and physical medicine/rehabilitation (12.0%) [2] . However, following an overall peak in 2011, and in 2012 for hospitals, there has been a gradual decline in opioid distribution [3, 4] . Despite these reductions, the amount of opioids prescribed in 2015 [5] was almost three-fold higher than 1999 [6] . This upward trend may have been attributable to an increased prevalence of chronic pain, a limited knowledge regarding long-term opioid use, and capitalization on false claims regarding the non-addictive nature of opioids by pharmaceutical companies [7] . The morphine milligram equivalent (MME) per capita in 2016 in the US was 1,124 [3] , which is appreciably higher than other developed countries [8] or the US Territories [9] . However, even this belies the pronounced variability between states. There was a five-fold difference between the lowest (North Dakota = 485) and highest (Rhode Island = 2,624) states [3] . Examination of individual opioids [10, 11] revealed a three-fold state-level difference for fentanyl [12] , eighteen-fold for meperidine [13] , and twentyfold for buprenorphine [14] . This study aimed to identify patterns in the production and distribution between 2010 and 2019 of ten prescription opioids used primarily for pain. This range was chosen as it both includes and follows the implementation of legislative changes in most states intended to limit the distribution of opioids [12, 15] but is also prior to the COVID-19 pandemic and associated drug shortages [16] . Associations among state-level use of individual opioids were also determined. By identifying the state(s) with the highest and lowest declines in distribution as well as quantifying this variation, regional differences in efforts to combat the opioid epidemic can be examined. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint Opioid production data were obtained from the US Drug Enforcement Administration's (DEA) Production Quotas System [17], and opioid distribution data from their Automation of Reports and Consolidated Orders System (ARCOS). ARCOS is a publicly available reporting system mandated by the DEA that reports detailed and comprehensive drug information from manufacturing to distribution [18] . ARCOS data corresponds highly with state prescription drug monitoring programs [3, 19] and has been used in many prior investigations [3, 4, 9-16, 19, 20] . Information on ten Schedule II opioid prescription drugs used for the treatment of pain: codeine, fentanyl base, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol, were collected. Buprenorphine [14] was excluded because it is primarily employed for opioid use disorder. All procedures were approved by Geisinger and the University of New England's Institutional Review Board. The oral MME for each opioid drug was determined using the appropriate multipliers: codeine 0.15, fentanyl base 75, hydrocodone 1, hydromorphone 4, meperidine 0.1, methadone 8, morphine 1, oxycodone 1.5, oxymorphone 3, and tapentadol 0.4 [3, 4] and summed for all ten opioids across all 50 states. Methadone [10] , when utilized for the treatment of opioid use disorder, was excluded (note that there is no similar mechanism in the production quotas to differentiate subsequent pain versus narcotic treatment program use). The weight in grams of each opioid was obtained from ARCOS from 2010 to 2019 to isolate the peak opioid distribution year. Heat maps demonstrating the percent change across all 50 states per capita were produced using JMP. The per capita use of each opioid drug for each state was calculated using the respective population estimate from the American Community Survey [21] . Ratios for the highest to lowest states and for the 95 th : 5 th and 70 th : 30 th percentiles were calculated using these values [22] . Spearman correlations were calculated between each opioid for per capita distribution. The standard error of the mean (SEM) depicted variability. A Fisher r to Z transformation was completed to determine if the correlations differed between 2011 and 2019. All figures were constructed using the Graphpad Prism version 8. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint difference between the highest (Florida = -61.61%) and lowest (Texas = -18.64%) states for the decline in opioid distribution. Figure 2E demonstrates the observed percent difference for a total opioid distribution during this period and showed that other states with sizable ( > 50%) reductions were Nevada (-59.7%), Ohio (-57.4%), Tennessee (-55.2%), Maine (-54.4%), Oregon (-54.3%), and West Virginia (-50.9%). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint Figure 3 shows the ratios between the 95 th : 5 th percentiles for the population corrected distribution of each Schedule II opioid for 2011, the peak year, and 2019. This ratio was highest for oxymorphone (7.97) and meperidine (7.30) and smallest for codeine (2.40) and fentanyl is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint capita distribution included Texas (oxycodone and morphine), Hawaii (fentanyl and hydromorphone), and Minnesota (oxymorphone and tapentadol) in 2019 (Supplemental Table 1 ) Table 1 shows correlations in the MME per capita per state between each opioid. Oxycodone had the most significant correlations with the other opioids in both 2011 and 2019. In 2011, there were three, mostly moderate (r = 0.35-0.69), correlations between oxycodone with morphine, oxymorphone, and methadone. Moreover, there were also moderate associations between hydrocodone and meperidine, and between oxymorphone and tapentadol. In 2019, there were three moderate correlations between oxycodone with morphine, oxymorphone, and methadone. There were also moderate correlations between hydrocodone with meperidine and codeine. Fischer r to Z statistics were calculated to identify differences in the strength of the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint correlations between opioids in 2011 relative to 2019. These analyses revealed a significant difference, i.e. an increase, in the magnitude of association between codeine and hydrocodone (p < 0.05), codeine and hydromorphone (p < 0.01), hydrocodone and methadone (p < 0.05), and methadone and oxycodone (p < 0.05). Comparisons between the averages of the correlations were then completed for each opioid with each other opioid. A significant difference was identified in the mean correlation between 2011 and 2019 for methadone (p < 0.05). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint There are several findings from this investigation on the dynamic changes but also sizable regional variance in the distribution of prescription opioids in the US. This study determined that prescription opioids for pain have undergone a pronounced reduction over the past decade, which is congruent with and extends upon reports from earlier periods [2-6, 12]. This report identified a consistent decline in opioid distribution since 2011, the peak year [3] . There are a myriad of reasons that may explain the decline including increased awareness of the addictive nature of opioids [7] , continued escalation in opioid-related overdose mortalities [1] , and the increased government funding and resources resulting from the classification of the opioid crisis as a public health emergency [23] . Evidence has been more subtle or contradictory for any measurable impact of Prescription Drug Monitoring Programs [24, 25] or state opioid prescribing laws [12, 15] . Although there has been much prior attention to opioid distribution [2-6, [9] [10] [11] [12] [13] [14] [15] . It did not escape notice that the total production quotas ( Figure 1A) were about three-fold higher than opioid distribution ( Figure 1B) . One caveat is that distribution only included methadone when used for pain while the distribution included methadone that was subsequently employed for both pain and at narcotic treatment programs. By MME, methadone is by far the predominant prescription opioid in the US [3] . Examination of eleven opioids in ARCOS by zip code revealed that methadone could account for as much as four-fifths of the total [26] . The production of methadone for addiction treatment may account for a portion of the excess of production relative to distribution but a more important factor is the production quota is inclusive of opioids that are subsequently exported [27] . The total opioid distribution declined since 2011 despite the increase in total opioid production between 2011 to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. which extends upon prior reports [11, 12] . There may be some parallels between regional differences in prescription opioid use and drug overdoses. Drug overdose deaths have not homogeneously impacted the US [1] . Although death determination is a highly complicated process and data should be interpreted cautiously because of methodological differences between states [32] , the eastern US has had more overdoses [1] . Similarly, opioid distribution was not homogeneous. Total per-capita opioid distribution from 2011 was significantly elevated in Tennessee, Nevada, Delaware, and Florida relative to the national mean. When analyzing the total per capita opioid distribution in 2019, only two states, Alabama and Delaware, were significantly higher than the national mean. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint Further, when analyzing the data nationally, Florida [9] had the highest per capita opioid distribution decline while Texas [33] had the lowest decline. We can speculate that the general allowance of state discretion on what policies to implement and how to implement/enforce them may play a role in these observed differences in progress towards decreasing opioid distribution. There were several positive correlations between opioid distribution per person per state. Interestingly, both 2011 and 2019 showed multiple associations with oxycodone. This finding may suggest that there may be a link between the tendency of being prescribed a correlated opioid medication, such as oxycodone, alongside the original prescribed opioid medication. Strong correlations were also found for codeine and hydrocodone, codeine and hydromorphone, hydrocodone and methadone, and methadone and oxycodone. As alluded to earlier, the shift away from prescribing methadone for analgesia may also explain our observation between methadone and hydrocodone exhibiting the strongest negative correlation in 2019. The prevailing indication for methadone production in 2019 [10] (opioid use disorder) is different from the indication for hydrocodone (pain). However, additional studies should explore the influence on treatment decisions at the patient level to further explore these opioid associations. It is very likely that medical specialty preferences exist for the choice of opioid medication based on knowledge of opioid pharmacology, comfort level, and experience. For example, otolaryngologists commonly prescribe hydrocodone and oxycodone, while family medicine physicians tend to prescribe buprenorphine [34] [35] [36] . While we successfully identified changes in Schedule II opioid production and distribution between 2011 and 2019 and greatly extended upon prior investigations [2, 3, 9-14, 23, 26, 33] to explore the substantial regional variation [37], this study was not without caveats. We reported a decline in opioid distribution beginning in 2011 based on the distribution rates of the opioids as mentioned earlier. However, other commonly prescribed opioids for opioid use disorder such as buprenorphine [14] were not included in our analysis and may have influenced the peak year of opioid distribution. In addition, ARCOS data does not account for Schedule IV or V opioids that could influence the total opioid distribution across the US [34] . For example, tramadol was moved to Schedule IV in 2014 [38] . The MMEs per capita would be even higher with the inclusion of additional non-Schedule II opioids. Moreover, the effects of racial, gender and socioeconomic disparities were not examined here but have been explored by others [39] [40] [41] [42] [43] . Stratifying data based on these demographics could identify more specific changes, and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint continued disparities, in opioid distribution. Overall, this study found dynamic changes in prescription opioid production and sizable but gradual reductions in distribution the US from 2010 to 2019. We speculate that this decline might result from factors such as increased government funding and resources, and an overall increased understanding of the addictive nature of opioids. More research on the prevalence of these opioids is necessary to weaken their grip on society. Further, the non-homogenous nature of opioid distribution and its effects on the population pose a barrier to continued efforts to oneday overcoming the US opioid epidemic. Further investigations of state and county level differences may inform the policies of opioid stewardship programs. We would like to thank Geisinger Commonwealth School of Medicine for supporting this research and the Biomedical Research Club for technical assistance. We thank the Drug Enforcement Administration for making the Automated Reports and Consolidated Orders System dataset publicly available. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266660 doi: medRxiv preprint Trends in opioid analgesic-prescribing rates by specialty Trends in medical use of opioids in the Declines and regional variation in opioid distribution to U.S. hospitals Vital Signs: Changes in opioid prescribing in the United States The opioid epidemic in the United States -Overview, origins and potential solutions. Cancer Patterns, changes, and trends in prescription opioid dispensing in Canada Opioid distribution trends (2006-2017) in the US Territories Pronounced regional disparities in United States methadone distribution Pronounced declines in dispensed licit fentanyl, but not fentanyl derivatives Trends in the medical supply of fentanyl and fentanyl analogues: United States Declines and pronounced regional disparities in meperidine use in the United States Rise and regional disparities in buprenorphine utilization in the United States Opioid prescribing laws are not associated with short-term declines in prescription opioid distribution production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment 18. Department of Justice, ARCOS retail summary reports Finite mixture modeling of change point processes to discover opioid prescribing patterns: A case study of Automated Reports and Consolidated Ordering System data Variation in outpatient antibiotic prescribing in the United States Jones CM What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis County and demographic differences in drug arrests and controlled substance use in Maine Opioid mortality following implementation of medical cannabis programs in the United States Dynamic changes in prescription opioids from 2006 to 2017 in Texas Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty Opioid prescribing patterns among otolaryngologists Prescription and prescriber specialty characteristics of initial opioid prescriptions associated with chronic use Sex differences among opioid-abusing chronic pain patients in a clinical trial Assessment of racial/ethnic and income disparities in the prescription of opioids and other controlled medications in California Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse Variation in adult outpatient opioid prescription dispensing by age and sex-United States Racial differences in prescription of opioid analgesics for chronic noncancer pain in a national sample of veterans